"Retina Associates of Western NY (RAWNY) is a highly specialized group of physicians that care for and treat diseases of the retina and vitreous. We are dedicated to working closely with your referring doctor to make your visit a comfortable experience while providing the highest quality care possible. We employ state of the art diagnostic equipment along with the latest surgical and pharmaceutical innovations in order to provide exceptional vitreoretinal care."

During the past decade, Retina Associates of Western New York conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 16 clinical trials were completed, i.e. on average, 57.1% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 13 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Retina Associates of Western New York" #1 sponsor was "Hoffmann-La Roche" with 10 trials, followed by "Jaeb Center for Health Research" with 5 trials sponsored, "Allergan" with 3 trials sponsored, "Kodiak Sciences Inc" with 3 trials sponsored and "Genentech, Inc." with 3 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retina Associates of Western New York" #1 collaborator was "National Eye Institute (NEI)" with 4 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "Novartis Pharmaceuticals" with 2 trials as a collaborator, "Regeneron Pharmaceuticals" with 2 trials as a collaborator and "Allergan" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Retina Associates of Western New York" are "Diabetic Macular Edema" (9 trials), "Macular Degeneration" (6 trials), "Geographic Atrophy" (5 trials), "Macular Edema" (3 trials) and "Central Retinal Vein Occlusion" (2 trials). Many other conditions were trialed in "Retina Associates of Western New York" in a lesser frequency.

Most popular intervention types in "Retina Associates of Western New York" are "Drug" (30 trials), "Other" (9 trials), "Procedure" (5 trials), "Biological" (1 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (11 trials), "Aflibercept" (6 trials), "Faricimab" (6 trials), "Ranibizumab" (5 trials) and "KSI-301" (3 trials). Other intervention names were less common.

The vast majority of trials in "Retina Associates of Western New York" are 32 trials for "All" genders.

Currently, there are NaN active trials in "Retina Associates of Western New York". undefined are not yet recruiting, 3 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Retina Associates of Western New York, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Retina Associates of Western New York, 0 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".